On-Body Sensor Allows for Continuous Patient Monitoring At Home

The Food and Drug Administration has granted 510(k) clearance to BioSticker™, a physician-prescribed on-body sensor that can monitor patient vital signs for up to 30 days and remotely deliver data to the clinician.

BioIntelliSense, the developers of the single-use medical device and the monitoring platform, announced the commercial launch today. The sensor is designed to be worn on the upper left chest, where it can measure information such as heart rate, respiratory rate, skin temperature, and symptomatic events. 

The Company’s Data-as-a-Service platform captures continuous patient data, providing clinicians with a comprehensive overview of the patient’s condition. “The use of the BioSticker device for continuous health monitoring enables us to monitor a patient in their home and recognize when a patient may have an exacerbation of illness even before they manifest symptoms,” said Dr Richard Zane, UCHealth Chief Innovation Officer and Chair of Emergency Medicine at the University of Colorado School of Medicine. “This may reduce hospitalizations, emergency department visits and shorten hospital stays, creating cost efficiencies for health systems.”

For more information visit biointellisense.com.